[go: up one dir, main page]

TR199801069T2 - Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen türevleri ve bunlarin terapötik kullanimi - Google Patents

Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen türevleri ve bunlarin terapötik kullanimi

Info

Publication number
TR199801069T2
TR199801069T2 TR1998/01069T TR9801069T TR199801069T2 TR 199801069 T2 TR199801069 T2 TR 199801069T2 TR 1998/01069 T TR1998/01069 T TR 1998/01069T TR 9801069 T TR9801069 T TR 9801069T TR 199801069 T2 TR199801069 T2 TR 199801069T2
Authority
TR
Turkey
Prior art keywords
trisiklik
revleri
kullan
diokso
bynar
Prior art date
Application number
TR1998/01069T
Other languages
English (en)
Inventor
Boutherin- Falson Odile
Desquand- Billiald Stephanie
Favrou Anita
Finet Michel
Tembo Oliver
Torregrosa Jean-Luc
Yannic-Arnoult Sylvie
Domagala-Le Marquer Florence
Original Assignee
Laboratoire Innothera, Societe Anonyme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Innothera, Societe Anonyme filed Critical Laboratoire Innothera, Societe Anonyme
Publication of TR199801069T2 publication Critical patent/TR199801069T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Damar fonksiyonu yetmezligi ve/veya enflamatuar ödem ile ilgili hastaliklarin tedavisi için genel formül (I)' i havi trisiklik türevler ve bunlarin farmasötik yönden kabul edilebilir tuzlari tarif edilmektedir.
TR1998/01069T 1995-12-12 1996-12-10 Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen türevleri ve bunlarin terapötik kullanimi TR199801069T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514683A FR2742153B1 (fr) 1995-12-12 1995-12-12 Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TR199801069T2 true TR199801069T2 (tr) 1998-08-21

Family

ID=9485393

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01069T TR199801069T2 (tr) 1995-12-12 1996-12-10 Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen türevleri ve bunlarin terapötik kullanimi

Country Status (26)

Country Link
US (1) US6262095B1 (tr)
EP (1) EP0876356B1 (tr)
JP (1) JP2000501724A (tr)
KR (1) KR19990072080A (tr)
AP (1) AP889A (tr)
AR (1) AR005054A1 (tr)
AT (1) ATE207907T1 (tr)
AU (1) AU716199B2 (tr)
BR (1) BR9611935A (tr)
CA (1) CA2240279A1 (tr)
CZ (1) CZ181198A3 (tr)
DE (1) DE69616598D1 (tr)
EE (1) EE9800174A (tr)
FR (1) FR2742153B1 (tr)
HU (1) HUP9901247A3 (tr)
ID (1) ID16081A (tr)
IL (1) IL124558A0 (tr)
LT (1) LT4491B (tr)
LV (1) LV12188B (tr)
NO (1) NO982696L (tr)
NZ (1) NZ323967A (tr)
OA (1) OA10696A (tr)
PL (1) PL327168A1 (tr)
RU (1) RU2178791C2 (tr)
TR (1) TR199801069T2 (tr)
WO (1) WO1997021684A1 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032115A1 (en) * 1997-12-19 1999-07-01 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
US7754463B2 (en) 2006-06-20 2010-07-13 Dana-Farber Cancer Institute Inhibitors of USP1 Deubiquitinating Enzyme Complex
US9518032B2 (en) 2010-04-30 2016-12-13 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of USP1 deubiquitinating enzyme activity
US9040713B2 (en) * 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
RU2545091C1 (ru) * 2014-03-18 2015-03-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039925A (en) 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US4746676A (en) 1984-09-12 1988-05-24 Rorer Pharmaceutical Corporation Carboxyalkyl dipeptide compounds
JPH05112533A (ja) * 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
WO1994003439A1 (en) * 1992-07-29 1994-02-17 Agouron Pharmaceuticals, Inc. Antiproliferative tricyclic compounds

Also Published As

Publication number Publication date
WO1997021684A1 (fr) 1997-06-19
AP889A (en) 2000-11-17
EP0876356A1 (fr) 1998-11-11
US6262095B1 (en) 2001-07-17
PL327168A1 (en) 1998-11-23
FR2742153A1 (fr) 1997-06-13
LT98085A (en) 1998-11-25
AU716199B2 (en) 2000-02-24
KR19990072080A (ko) 1999-09-27
EP0876356B1 (fr) 2001-10-31
ATE207907T1 (de) 2001-11-15
LT4491B (lt) 1999-04-26
IL124558A0 (en) 1998-12-06
HUP9901247A2 (hu) 1999-08-30
DE69616598D1 (de) 2001-12-06
OA10696A (fr) 2002-11-26
NO982696L (no) 1998-08-11
ID16081A (id) 1997-09-04
NO982696D0 (no) 1998-06-11
HUP9901247A3 (en) 2000-08-28
FR2742153B1 (fr) 1998-02-13
AR005054A1 (es) 1999-04-07
BR9611935A (pt) 1999-05-18
CZ181198A3 (cs) 1998-09-16
RU2178791C2 (ru) 2002-01-27
AU1101897A (en) 1997-07-03
CA2240279A1 (fr) 1997-06-19
EE9800174A (et) 1998-12-15
JP2000501724A (ja) 2000-02-15
NZ323967A (en) 2000-06-23
LV12188A (lv) 1998-12-20
LV12188B (en) 1999-07-20
AP9801275A0 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
CA2086434A1 (en) Quinuclidine derivatives
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
YU56492A (sh) Derivati hinuklidina
DE69310367D1 (de) Anilide-derivate
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
SE7611379L (sv) Antihypertensiva medel
TNSN94104A1 (fr) Composes carbamates tricycliques utiles pour l'inhibition de la fonction proteine g et pour le traitement des maladies proliferatives
TR199802060T2 (tr) Aminoisokinolinler ve aminopiridin türevlerinin iltihap önleyiciler olarak kullanimi.
TR199801195T2 (tr) Tedavide yararli kinolin ve kinozilin bilesikleri.
ATE297208T1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
ATE165830T1 (de) Dihydro pyrazolopyrrole
FR2686084B1 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
DK0873351T3 (da) Steroidnitrit/nitratesterderivater anvendelige som antiinflammatoriske lægemidler
DE69623899D1 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
MX9301197A (es) Derivados de indol.
DK0665834T3 (da) Quinolon- og acridinonderivater til behandling af urininkontinens
TR199801069T2 (tr) Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen türevleri ve bunlarin terapötik kullanimi
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
ATE242220T1 (de) Benzimidazolderivate mit dopaminerger wirkung
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin